Slug contributes to cancer progression by direct regulation of ERα signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Hormone therapy targeting estrogen receptor alpha (ERα) is a primary breast cancer treatment.
• Treatment failure due to endocrine resistance is a significant clinical challenge.
• Mechanisms of ERα downregulation in endocrine resistance remain incompletely understood.

Purpose of the Study:

• To investigate the role of Slug in ERα expression regulation and endocrine resistance.
• To elucidate the Slug-ERα signaling pathway in breast and prostate cancer.
• To assess Slug as a potential therapeutic target for overcoming endocrine resistance.

Main Methods:

• Analysis of Slug and ERα expression in patient samples (breast and prostate cancer).
• Utilized resistant (MCF-TAMR) and high-Slug (MDA-MB-231) cell lines for functional studies.
• Performed Slug knockdown and assessed changes in cell phenotype, activity, and drug response.
• Conducted microarray analysis and chromatin immunoprecipitation to study Slug-ERα interactions.

Main Results:

• Slug expression inversely correlates with ERα levels in cancer patient samples.
• Slug overexpression is observed in high-grade breast and prostate cancers, correlating with drug resistance.
• Slug directly binds to ERα promoter E-boxes, repressing ERα expression.
• Slug inhibition reversed mesenchymal phenotypes and potentially impacts stem cell activity.

Conclusions:

• Slug acts as a key transcription factor that represses ERα expression, contributing to endocrine resistance.
• Slug plays a role in tumor progression and epithelial-to-mesenchymal transition.
• Targeting Slug presents a promising therapeutic strategy to overcome endocrine resistance in ERα-positive cancers.